Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance and pharmacokinetics study of oral [14C]BAY 2433334 in healthy male volunteers
NL-OMON50127Active, not recruiting
- Sponsor
- Bayer
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of asundexian in thromboembolism and stroke, sponsored by Bayer. Primary endpoints: Mass balance of total radioactivity, Pharmacokinetics of total radioactivity in plasma and whole blood and 1 more. Started Jan 2020; status: active, not recruiting.
02
Drugs
asundexian
03
Conditions
thromboembolismstroke
Beyond the preview
Go deeper on NL-OMON50127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50127.